Oslo, 7 October 2025: Reference is made to the stock exchange announcement published by Navamedic ASA (the “Company“) earlier today regarding the final result of the rights issue in the Company (the “Rights Issue“).

Certain primary insiders, and certain close associates of primary insiders, of the Company have been allocated shares in the Rights Issue:

Soleglad Invest AS, a company closely associated with Kathrine Elisabeth Gamborg Andreassen, CEO of the Company, has been allocated 23,260 new shares.

Jostein Davidsen, Chairperson of the Board of Directors of the Company, has been allocated 17,116 new shares.

Philip Slätis, Commercial Director RX & International of the Company, has been allocated 3,422 new shares.

Tranbergkollen Invest AS, a company closely associated with Astrid T. Bratvedt, Chief Scientific Officer of the Company, has been allocated 25,000 new shares.

Jurs AS, a company closely associated with Morten Jurs, board member of the Company, has been allocated 7,851 new shares.

Please see the attached forms for further details about the transactions.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.